Vobarilizumab (ALX-0061) was intended to eliminate symptoms of rheumatoid arthritis and systemic lupus erythematosus by blocking the interleukin-6 receptor [66,67]. This evidence concerns the gene IL6R and systemic lupus erythematosus.